These studies suggest that mGluR1/5 reduction may play a common physiological role in the development of epilepsy and schizophrenia and that compounds that enhance mGluR1/5 activity may have the potential to be developed as novel anti-POE drugs. Here, GRM1 is linked to schizophrenia.